pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Fabhalta
drug · small molecule
save

iptacopan hydrochloride

Marketedupdated 6mo ago
by $NVS NOVARTIS AG🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for paroxysmal nocturnal hemoglobinuria and iga glomerulonephritis and 2 investigational indications.

targets

Complement factor B

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 7, 2027
258 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Jul 15, 2041method-of-use (U-3895)US 11951101
  • Jul 15, 2041method-of-use (U-4300)US 12453726
  • May 25, 2041compositionUS 11603363
  • May 17, 2041method-of-use (U-4161)US 12384758
  • Aug 30, 2038method-of-use (U-3980)US 11723901
  • Aug 30, 2038method-of-use (U-4181)US 12285422
  • Jul 14, 2034method-of-use (U-3980)US 10093663
  • Jul 14, 2034compositionUS 9682968

FDA exclusivities (4)

  • Dec 5, 2030ODE-456Orphan Drug (7y)4.0y
  • Dec 5, 2028NCENew Chemical Entity (5y)2.0y
  • Mar 20, 2028I-963Indication (3y)1.3y
  • Aug 7, 2027I-949Indication (3y)258d

News(10)

  • Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
    Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting up “the next wave” for Vertex Pharmaceuticals.
    biospace · 4d ago
  • Deaths, failed trials and other recent setbacks in the autoimmune space
    Novartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…
    biospace · 5d ago
  • Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
    Also lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.
    biospace · 15d ago
  • Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
    Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
    biospace · 25d ago
  • Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
    Roche's Genentech has put numbers behind its phase 3 success in IgA nephropathy (IgAN), reporting that antisense oligonucleotide sefaxersen reduced a key marker of kidney damage by 43.1% compared w…
    fiercebiotech · 29d ago
  • Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
    Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset.
    fiercebiotech · 1mo ago
  • Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
    Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read o…
    biospace · 1mo ago
  • Novartis scraps Fabhalta study in lupus nephritis
    Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a federal clinical trials database. Fabhalta, also known as iptacopan, is a key…
    endpoints · 1mo ago
  • Roche, Ionis RNA drug scores in kidney disease study
    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
    biopharma_dive · 1mo ago
  • Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
    Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.
    fiercebiotech · 1mo ago
view all news mentions →
brand
Fabhalta
trade names
Fabhalta
generic
iptacopan hydrochloride
MOA
Complement factor B inhibitor
indication
Myasthenia Gravis
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?